BTIG Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $308
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $325
Truist Financial Sticks to Their Buy Rating for Penumbra (PEN)
Stifel Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $301
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Astrana Health (ASTH) and Penumbra (PEN)
Penumbra (PEN) Receives a Buy From Leerink Partners
J.P. Morgan Maintains Penumbra(PEN.US) With Hold Rating, Raises Target Price to $285
Penumbra Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $313
Penumbra Is Maintained at Buy by UBS
Penumbra Price Target Raised to $320.00/Share From $305.00 by UBS
RBC Capital Adjusts Price Target on Penumbra to $313 From $285, Keeps Outperform Rating
Penumbra Price Target Raised to $305.00/Share From $275.00 by Wells Fargo
Penumbra Is Maintained at Overweight by Wells Fargo
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $325
Jefferies Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $308
Penumbra Is Maintained at Equal-Weight by Morgan Stanley
A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $305 to $340
Penumbra Is Maintained at Outperform by Baird
Penumbra Analyst Ratings
Unlock the Full List